U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07155629) titled 'Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer' on Aug. 25.
Brief Summary: Pancreatic cancer is one of the most treatment resistant malignancies, often diagnosed at a late stage and associated with poor survival. The 5-year overall survival rate remains around 10%. Prognosis is affected by multiple factors including tumor stage, biology, treatment response, and anatomical location. Distal (left-sided) pancreatic cancer, originating from the body or tail of the pancreas, accounts for approximately 20-25% of all pancreatic cancers and has been associated with worse survival than pancreatic head cancer, even ...